The Board of Directors of Windlas Biotech Limited, in its meeting held on February 5, 2026, approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. For the third quarter (Q3 FY2025-26), the company reported consolidated revenue from operations of ₹2,323.51 million, representing a 4.48% increase from the previous quarter’s ₹2,223.92 million and a 19.14% increase from ₹1,950.21 million in the corresponding quarter of the previous year. Consolidated net profit for the quarter stood at ₹177.34 million, showing a marginal decrease of 0.37% from ₹178.00 million in the preceding quarter and a 13.82% increase compared to ₹155.80 million in the same period last year.

Windlas Biotech Limited, established in 2001, is a leading Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing comprehensive services from product discovery to commercial manufacturing. The company operates through three strategic verticals: Generic Formulations CDMO, Domestic Trade Generics and OTC Brands, and Exports. In 2025, Windlas focused on expanding its export presence, particularly in the U.S. market, and enhancing infrastructure with the commissioning of its Plant-2 extension facility. Recent updates include the Board’s approval on February 5, 2026, to dissolve its non-operative US subsidiary, Windlas Inc.. Major institutional investors as of 2025 include ICICI Prudential Asset Management and Persistence Capital Fund.